Are Wall Street Analysts Bullish on Agilent Technologies Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Source: NASDAQ.COM
Company Overview and Performance: Agilent Technologies, valued at $38.5 billion, has underperformed the market with a 6.1% gain over the past year compared to the S&P 500's 32.1% increase, and is down 3.4% in 2024 against the SPX's 26.2% rise.
Analyst Ratings and Future Expectations: Despite recent Q4 results beating expectations, analysts project a decline in EPS for the current fiscal year; however, the consensus rating remains a "Moderate Buy" with price targets suggesting potential upside from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 115.080
Low
160.00
Averages
171.67
High
180.00
Current: 115.080
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilent Technologies Reports Strong Earnings, Exceeding Revenue Guidance
- Revenue Growth Exceeds Expectations: Agilent Technologies reported revenue of $1.83 billion with a core growth rate of 6.3%, surpassing guidance by 80 basis points, indicating strong performance in key markets, particularly in pharmaceuticals and chemical materials.
- Significant Margin Improvement: The company achieved an operating margin of 26.4%, up 130 basis points year-over-year, driven by the implementation of the Ignite operating system, which enhanced strategic pricing and operational efficiencies, thereby boosting overall profitability.
- Earnings Per Share Growth: EPS reached $1.49, reflecting a 14% year-over-year increase and exceeding guidance by $0.07, showcasing the company's competitive edge and ongoing improvement in profitability.
- Optimistic Future Outlook: The company provided full-year revenue guidance of $7.39 billion to $7.49 billion, with core growth projected at 4.5% to 6%, and raised EPS guidance to $6 to $6.10, demonstrating management's confidence in future growth prospects.
See More
Agilent (A) Q2 2026 Earnings Call Transcript
See More
Multiple Companies Report Earnings Beats, Stock Movements
- Salesforce Guidance Adjustment: Salesforce guided for current-quarter revenue between $11.27 billion and $11.35 billion, slightly below analysts' expectations of $11.36 billion, although the company raised its full-year earnings guidance, indicating confidence in future growth.
- Nutanix Strong Earnings: Nutanix reported fiscal third-quarter adjusted earnings and revenue beats, with a non-GAAP operating margin of 22.3%, significantly exceeding analysts' call for 16.9%, reflecting the company's robust performance in the cloud computing sector.
- Agilent Raises Earnings Outlook: Agilent Technologies shares surged 11% after raising its full-year adjusted earnings guidance to between $6 and $6.10 per share, higher than previous estimates of $5.90 to $6.04, demonstrating strong demand in the healthcare equipment market.
- Snowflake Soars: Snowflake's stock jumped 33% in after-hours trading after announcing a $6 billion investment plan in Amazon Web Services over five years, alongside first-quarter results that surpassed estimates, showcasing its enhanced market competitiveness.
See More
Agilent Technologies Q2 Earnings Beat Expectations, Stock Rises 10%
- Strong Financial Performance: Agilent Technologies reported Q2 non-GAAP EPS of $1.49, beating expectations by $0.08, with revenue of $1.83 billion exceeding forecasts by $30 million, indicating robust market performance.
- Upgraded Fiscal 2026 Guidance: The company raised its fiscal 2026 revenue guidance to a range of $7.39 billion to $7.49 billion, up from the previous $7.3 billion to $7.5 billion, reflecting confidence in future growth prospects.
- Life Sciences Market Growth: Agilent achieved a 12% year-over-year revenue growth in its Life Sciences and Diagnostics Markets Group, reaching $732 million, demonstrating sustained demand in this sector and contributing to overall performance.
- Stable Cash Flow: As of April 30, the company reported cash and cash equivalents of approximately $1.8 billion, consistent with the figure from October 31, 2025, indicating strong financial health and providing a solid foundation for future investments.
See More
Agilent Technologies Q2 Earnings Beat Expectations
- Earnings Surprise: Agilent Technologies reported a Q2 non-GAAP EPS of $1.49, beating expectations by $0.08, indicating a robust profitability trend that strengthens market confidence.
- Significant Revenue Growth: The company achieved revenue of $1.83 billion, a 9.6% year-over-year increase, surpassing market expectations by $30 million, reflecting strong demand and an increase in market share in the biotech sector.
- Fiscal Year 2026 Outlook: Revenue for FY 2026 is projected to be between $7.39 billion and $7.49 billion, below the consensus of $10.95 billion, yet indicating a growth potential of 6.3% to 7.8%, showcasing a cautious optimism for the future.
- Margin Improvement: The expected non-GAAP operating margin expansion for FY 2026 is now 85 basis points at the midpoint of core revenue growth guidance, an increase of 10 basis points, demonstrating ongoing efforts in cost control and operational efficiency.
See More
RBC Reiterates 'Outperform' Rating on Agilent Technologies with $153 Target
- Rating Reaffirmation and Target Price: RBC Capital Markets reiterated its 'outperform' rating on Agilent Technologies and set a price target of $153, reflecting confidence in the company's future performance.
- Organic Growth Expectations: RBC anticipates Agilent's organic sales growth rate to be 5.5% from 2026 to 2028, surpassing peers' 4.5%, indicating a competitive edge in the industry.
- Valuation Analysis: The target price is based on approximately 18 times forward EBITDA, slightly above the peer median of 16.5 times, suggesting market recognition of Agilent's future profitability.
- Risk Advisory: RBC cautioned that Agilent is more sensitive to macroeconomic cycles than its peers, particularly noting that 18% of its sales come from China, highlighting potential risks in industrial markets.
See More
Agilent Technologies Reports Strong Earnings, Exceeding Revenue Guidance
- Revenue Growth Exceeds Expectations: Agilent Technologies reported revenue of $1.83 billion with a core growth rate of 6.3%, surpassing guidance by 80 basis points, indicating strong performance in key markets, particularly in pharmaceuticals and chemical materials.
- Significant Margin Improvement: The company achieved an operating margin of 26.4%, up 130 basis points year-over-year, driven by the implementation of the Ignite operating system, which enhanced strategic pricing and operational efficiencies, thereby boosting overall profitability.
- Earnings Per Share Growth: EPS reached $1.49, reflecting a 14% year-over-year increase and exceeding guidance by $0.07, showcasing the company's competitive edge and ongoing improvement in profitability.
- Optimistic Future Outlook: The company provided full-year revenue guidance of $7.39 billion to $7.49 billion, with core growth projected at 4.5% to 6%, and raised EPS guidance to $6 to $6.10, demonstrating management's confidence in future growth prospects.
See More
Agilent (A) Q2 2026 Earnings Call Transcript
See More
Multiple Companies Report Earnings Beats, Stock Movements
- Salesforce Guidance Adjustment: Salesforce guided for current-quarter revenue between $11.27 billion and $11.35 billion, slightly below analysts' expectations of $11.36 billion, although the company raised its full-year earnings guidance, indicating confidence in future growth.
- Nutanix Strong Earnings: Nutanix reported fiscal third-quarter adjusted earnings and revenue beats, with a non-GAAP operating margin of 22.3%, significantly exceeding analysts' call for 16.9%, reflecting the company's robust performance in the cloud computing sector.
- Agilent Raises Earnings Outlook: Agilent Technologies shares surged 11% after raising its full-year adjusted earnings guidance to between $6 and $6.10 per share, higher than previous estimates of $5.90 to $6.04, demonstrating strong demand in the healthcare equipment market.
- Snowflake Soars: Snowflake's stock jumped 33% in after-hours trading after announcing a $6 billion investment plan in Amazon Web Services over five years, alongside first-quarter results that surpassed estimates, showcasing its enhanced market competitiveness.
See More
Agilent Technologies Q2 Earnings Beat Expectations, Stock Rises 10%
- Strong Financial Performance: Agilent Technologies reported Q2 non-GAAP EPS of $1.49, beating expectations by $0.08, with revenue of $1.83 billion exceeding forecasts by $30 million, indicating robust market performance.
- Upgraded Fiscal 2026 Guidance: The company raised its fiscal 2026 revenue guidance to a range of $7.39 billion to $7.49 billion, up from the previous $7.3 billion to $7.5 billion, reflecting confidence in future growth prospects.
- Life Sciences Market Growth: Agilent achieved a 12% year-over-year revenue growth in its Life Sciences and Diagnostics Markets Group, reaching $732 million, demonstrating sustained demand in this sector and contributing to overall performance.
- Stable Cash Flow: As of April 30, the company reported cash and cash equivalents of approximately $1.8 billion, consistent with the figure from October 31, 2025, indicating strong financial health and providing a solid foundation for future investments.
See More
Agilent Technologies Q2 Earnings Beat Expectations
- Earnings Surprise: Agilent Technologies reported a Q2 non-GAAP EPS of $1.49, beating expectations by $0.08, indicating a robust profitability trend that strengthens market confidence.
- Significant Revenue Growth: The company achieved revenue of $1.83 billion, a 9.6% year-over-year increase, surpassing market expectations by $30 million, reflecting strong demand and an increase in market share in the biotech sector.
- Fiscal Year 2026 Outlook: Revenue for FY 2026 is projected to be between $7.39 billion and $7.49 billion, below the consensus of $10.95 billion, yet indicating a growth potential of 6.3% to 7.8%, showcasing a cautious optimism for the future.
- Margin Improvement: The expected non-GAAP operating margin expansion for FY 2026 is now 85 basis points at the midpoint of core revenue growth guidance, an increase of 10 basis points, demonstrating ongoing efforts in cost control and operational efficiency.
See More
RBC Reiterates 'Outperform' Rating on Agilent Technologies with $153 Target
- Rating Reaffirmation and Target Price: RBC Capital Markets reiterated its 'outperform' rating on Agilent Technologies and set a price target of $153, reflecting confidence in the company's future performance.
- Organic Growth Expectations: RBC anticipates Agilent's organic sales growth rate to be 5.5% from 2026 to 2028, surpassing peers' 4.5%, indicating a competitive edge in the industry.
- Valuation Analysis: The target price is based on approximately 18 times forward EBITDA, slightly above the peer median of 16.5 times, suggesting market recognition of Agilent's future profitability.
- Risk Advisory: RBC cautioned that Agilent is more sensitive to macroeconomic cycles than its peers, particularly noting that 18% of its sales come from China, highlighting potential risks in industrial markets.
See More
